Coverage
— → Added to coverage
Current stock research snapshot · Not reviewed Date unavailable
ISRGIntuitive Surgical, Inc.
Investment conviction○○○○○0 of 5 · current snapshot
Research target—Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap$131.51BSnapshot value · Not reviewed
Research history
See all ISRG changes ↗What changed
Intuitive Surgical - robotic surgical systems (da Vinci). Dominant PA thesis: robotic surgery platforms (per skill: ISRG is physical_ai).
No published catalysts yet.
No published invalidation criteria yet.
No social-sentiment snapshot available.
Snapshot · Not reviewedNo positioning snapshot available.
Snapshot · Not reviewedTimestamped research update
Deep research update
802 words · Updated Aug 23, 2026
Research in development: this latest 802-word update is published for context while it is expanded toward the 1,000-word editorial standard.
Intuitive designs, manufactures, and markets the da Vinci surgical system (multi-port and SP single-port) and the Ion endoluminal system (robotic lung biopsy). It sells/leases the capital "razor" and then earns recurring "blade" revenue from proprietary instruments/accessories (limited-use, wear out per surgery) plus per-system service contracts. (Q2 2026 10-Q, Item 1)
FY2025 revenue $10.065B (+20.5% YoY from $8.352B), gross margin 66.0%, operating margin 29.3%, net income $2.856B. Q2 2026: revenue $2.892B, gross margin 67.8% (vs 66.3% Q2 2025), operating income $972M (33.6% margin, +31% YoY), net income $823.2M, diluted EPS $2.29. H1 2026 net income $1.6396B. (SEC companyfacts + Q2 2026 10-Q)
Surgical robotics is the highest-margin, most mature instance of "physical AI" — intelligence + actuation + perception taking a body. ISRG is not a software bridge; it is a hardware + consumables toll-road: the installed base of 11,710 da Vinci systems (each generating ~$752K/yr in recurring revenue) plus the surgeon-training lock-in and instrument razor/razor-blade make it a genuine chokepoint in robotic-assisted minimally-invasive surgery.
- Installed base 11,710 da Vinci systems as of 2026-06-30, +12% YoY (10,488 a year prior); 1,710 are da Vinci 5 (the newest generation), of which 136 OUS. (Q2 2026 10-Q)
- 468 da Vinci systems placed in Q2 2026 (+18% YoY from 395); 246 were da Vinci 5 (+37% from 180). Utilization (procedures/system/year) +3% YoY. (10-Q)
- ~892,000 da Vinci procedures in Q2 2026, +15% YoY; ~47,900 Ion procedures, +36% YoY. (10-Q)
- Razor/razor-blade realized economics: instruments & accessories revenue $1.73B (+18%) on ~892K procedures = $1,939 IA per procedure (within the disclosed $900–$3,700/procedure range). Service revenue $472M (+21%). Recurring (IA + service) = $2.20B = 76% of Q2 revenue. (10-Q)
- System ASP $0.6M–$3.1M (incl. ~1 yr service); service contracts $95K–$225K/yr; instruments have limited lives and must be replaced per surgery. (10-Q)
- Gross margin expansion 66.3% → 67.8% YoY = pricing-power proof; R&D $370.6M/Q (12.8% of revenue) is the "cost of the moat."
The moat is a three-layer lock-in, not a single patent: (1) Surgeon training + clinical data — 20+ years of proctored robotic-surgeon training and millions of procedures of da Vinci clinical/analytics data that a competitor cannot replicate in <5 years; (2) Installed base + instrument razor/razor-blade — proprietary limited-use instruments ($900–$3,700/procedure, no at-scale generic substitute) mean every installed system is an annuity; (3) Regulatory/clinical validation — FDA clearance + hospital credentialing for each procedure type. The quantitative constraint ISRG controls is the surgeon learning curve + instrument wear cycle: competitors (Medtronic Hugo, CMR Versius, J&J Ottava) have GA systems but single-digit combined share after a decade, because a hospital switching must retrain surgeons, re-buy capital, and abandon accumulated analytics — a 12+ month, multi-million-dollar requalification.
- GLP-1 obesity drugs (semaglutide/tirzepatide) suppress bariatric surgery volumes — a meaningful da Vinci procedure category; a structural decline in bariatric procedures would dent procedure-growth compounding.
- Medtronic Hugo / CMR Versius / J&J Ottava — credible GA substitutes with single-digit share today; a breakout (large hospital system adopting Hugo fleet-wide) would break the bypass test.
- Hospital capex cyclicality — systems are $0.6–3.1M capital purchases; a hospital-budget tightening cycle slows placements (the 468 placements/quarter is the swing factor).
- China exposure — meaningful OUS/China procedure base; local robotics competition (MicroPort MedBot, Edge Medical) and geopolitical/price pressure could cap growth in a key market.
- Valuation — ~43x TTM earnings on a $134B market cap leaves zero room for procedure-growth deceleration below ~15%; the thesis is priced for continued mid-teens compounding.
- What share of da Vinci 5 placements are upgrade/trade-in vs net-new hospitals? (net-new vs upgrade mix determines how much of the 468/quarter is true installed-base expansion vs refresh.)
- Is bariatric procedure growth already decelerating in 2026 on GLP-1 penetration, and what is bariatric as a % of total da Vinci procedures? (needs the 10-K procedure-category disclosure)
- Does a generic/third-party instrument alternative (e.g., aftermarket blades) have credible regulatory momentum? (would breach the razor/razor-blade annuity)
STRENGTHENED. The moat is intact and compounding: installed base +12%, procedures +15%, Ion +36%, gross margin expanding 66.3% → 67.8%, and 76% of revenue is recurring annuity. The toll-road is the surgeon-training + installed-base + instrument razor/razor-blade lock-in — genuinely hard to bypass within 18 months, with 80%-ish global share and no hyperscaler/Nvidia equivalent. The honest caveats: credible substitutes exist (bypass = PARTIAL, not clean), and the $134B / 43x valuation prices in continued mid-teens compounding, so the asymmetry is in durability of a toll-road, not an underpriced entry.